Troubled Immunocore Reawakens With New $130m Funding

Company Diversifies Into Hepatitis B

 
• By Andrew McConaghie

After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?

OXFORD, ENGLAND - JANUARY 25: A view on the streets in Oxford, England on 25 January, 2018
The Oxford, UK-headquartered company needs to generate proof of concept data for its T-cell receptor immunotherapy

More from Business

More from Scrip